Simultaneous Risk Factor Control Using Telehealth to slOw Progression of Diabetic Kidney Disease (STOP-DKD) study: Protocol and baseline characteristics of a randomized controlled trial

Clarissa Diamantidis, Hayden B. Bosworth, Megan M. Oakes, Clemontina A. Davenport, Jane F. Pendergast, Sejal Patel, Jivan Moaddeb, Huiman X. Barnhart, Peter D. Merrill, Khaula Baloch, Matthew J. Crowley, Uptal D. Patel

Research output: Contribution to journalArticle


Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease (ESKD) in the United States. Multiple risk factors contribute to DKD development, yet few interventions target more than a single DKD risk factor at a time. This manuscript describes the study protocol, recruitment, and baseline participant characteristics for the Simultaneous Risk Factor Control Using Telehealth to slOw Progression of Diabetic Kidney Disease (STOP-DKD) study. The STOP-DKD study is a randomized controlled trial designed to evaluate the effectiveness of a multifactorial behavioral and medication management intervention to mitigate kidney function decline at 3 years compared to usual care. The intervention consists of up to 36 monthly educational modules delivered via telephone by a study pharmacist, home blood pressure monitoring, and medication management recommendations delivered electronically to primary care physicians. Patients seen at seven primary care clinics in North Carolina, with diabetes and [1] uncontrolled hypertension and [2] evidence of kidney dysfunction (albuminuria or reduced estimated glomerular filtration rate [eGFR]) were eligible to participate. Study recruitment completed in December 2014. Of the 281 participants randomized, mean age at baseline was 61.9; 52% were male, 56% were Black, and most were high school graduates (89%). Baseline co-morbidity was high- mean blood pressure was 134/76 mmHg, mean body mass index was 35.7 kg/m2, mean eGFR was 80.7 ml/min/1.73 m2, and mean glycated hemoglobin was 8.0%. Experiences of recruiting and implementing a comprehensive DKD program to individuals at high risk seen in the primary care setting are provided. Trial Registration:NCT01829256.

Original languageEnglish (US)
Pages (from-to)28-39
Number of pages12
JournalContemporary Clinical Trials
Publication statusPublished - Jun 1 2018
Externally publishedYes



  • Behavioral intervention
  • Chronic kidney disease
  • Diabetes
  • Hypertension
  • Pharmacist
  • Randomized controlled trial
  • Telehealth

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this